The CEO of Aussie-listed Nutritional Growth Solutions says she’s delighted with the ‘significant’ positive results from the Aussie-listed supplement maker’s latest peer-reviewed clinical trials, on its Grow Daily Boys 10+ formula.

Speaking to Stockhead, Nutritional Growth Solutions (ASX:NGS) CEO and MD Liron Fendell said the new results, now published in the internationally peer-reviewed pediatric research journal –  Hormone Research in Pediatrics –  are more than just another endorsement of the company’s scientifically-based ambitions to aid growth development in kids and young people of all backgrounds.

“As children grow older the essential nutrients they require for optimal growth change – as does their ratio.

“What we can also take away from these clinical trials is the enormous value they provide in helping describe the reasons we create a range of different formulations specifically for boys or girls, at different ages and stages of growth.”

Kids need targeted support, especially kids which just aren’t responding to their particular nutritional environment.

NGS is now re-analysing the data sets which detail the positive results from the open extension phase (6-12 months) clinical trial results for the company’s Healthy Heights® Grow Daily Boys 10+ and which assessed the supplement’s impact on height, weight, and body composition in ‘healthy, lean, and short pre-adolescent 10 to 14.5-year-old males.’

Fendell told Stockhead the welcome results found ‘significant dose-response correlations’ between the consumption of Grow Daily Boys 10+ and the gain in height, weight, and muscle-mass.

The trial process began with six months of double-blinded intervention trials with the NGS nutritional formula or a placebo, which was followed up by another overlaying six months of trials using an open-label extension phase.

According to NGS, in the extension phase Grow Daily Boys 10+ was provided to all the participants in both the intervention and placebo groups – where some 79 healthy, lean, and short, pre-adolescent boys between 10 to 14.5 years old – completed the phase.

So what happened?

In short, the noticeably short participants who had at least 50% of the recommended daily dose of Grow Daily Boys 10+ for either six or 12 months maintained their average height increase rate throughout the year, while poor consumers (who consumed less than 50%) displayed a noticeable falling away in growth rate.

Lead researcher of the study, Dr Michal Yackobovitch-Gavan said assessment of the impact of nutritional support in older children and adolescents has historically been challenging.

“Differences in puberty timing and the tempo of change (can challenge outcomes).”

“Whereas the strength of this study lies in its one-year, two-phase design.”

Comprising six months of a double-blinded intervention, followed by an additional six months of an open-label extension, Dr Yackobovitch-Gavan said the trials provided depth and rigor due to the relatively large sample size, the trials long duration, and the evaluation of body composition.

“Through both phases we found that an intervention with a multi-nutrient, protein-rich formula was effective at improving the gain.”

Up, not out

Fendell says the other positive outcome throughout the extended study, was that net changes in fat mass and fat mass percentages were so minor.

What’s minor when we’re talking fat mass in minors (and fat mass percentages as well)?

According to pediatric standards, the average (or mean) changes of anything less than 0.8 kg for both fat mass and fat mass percentages confirm that the relevant intervention ‘has no obesogenic effect’ – which is possibly scientific manners for saying ‘makes you fat.’

All kids, everywhere

The global facing, Aussie-based health and nutrition company, which Fendell leads out of Tel Aviv in Israel and boasts some of Australia’s leading names in the global health supplement market – has been expanding its specialised product portfolio just as it’s been taking up real estate in the booming international supplement market.

“A key differentiator for Nutritional Growth Solutions is our ability to provide clinically proven nutrition solutions for children aged three to 15 years,” Fendell says.

“This latest phase for our Grow Daily Boys 10+ trial adds to the growing body of medical research to determine the optimal dose of the nutritional formula required to further improve the long-term growth responses in young children. It builds on more than 20 years research at the Schneider Children’s Medical Center, one of the leading institutions globally on child nutrition.”

According to Fendell, the Healthy Heights® range isn’t a blunt instrument targeting all the kids everywhere – with their different stages of growth, diets, environments and lifestyles just some of the many factors NGS research takes into account.

“It’s (Healthy Heights) simply just not a one-size-fits-all product.”

“This additional data provides us another layer of insight as Nutritional Growth Solutions steps up innovation across and increases the volume of channels through which our portfolio of products are available.”

And after a few years of sterling growth, there’s a lot of them.

Fendell told Stockhead Healthy Heights and other NGS brands are now breaking into new and exciting markets, available across the US, China, Israel, in Europe and all the way down into ASEAN.

“And these markets now include online retailers, pharmacies, health food stores, as well as literally hundreds of retailers around the states.”

In fact, just a few weeks back, the latest NGS deal with one of America’s leading natural food store operators – The Healthy Edge Group Inc. – not only expanded the NGS’ retail presence in the US, but it brings the full range to the shelves of an impressive 420 distinct retailers across the United States.

“So we’re thrilled – today’s results provide further momentum to our own strategic growth targets – and of course – they do something very similar for the parents we work with.”

This article was developed in collaboration with Nutritional Growth Solutions, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.